NMN/NR and Imaging Contrast Dye: What You Need to Know Before Your Scan

What the Evidence Actually Says About NMN/NR and Contrast Agents

No randomized controlled trial or published case report has documented a direct pharmacokinetic clash between nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) and contrast media. That absence of evidence does not mean the combination is risk-free, particularly in anyone whose kidneys are already under stress.

Why the Concern Exists at All

NMN and NR are both orally bioavailable NAD+ precursors. After absorption, they are converted through sequential enzymatic steps to NAD+ in the liver, red blood cells, and peripheral tissues [1]. The metabolic byproducts, including nicotinamide (NAM) and N-methyl-nicotinamide (MeNAM), are cleared renally [2]. Iodinated contrast agents used in CT angiography and coronary catheterization are also cleared almost entirely by glomerular filtration, with a plasma half-life of roughly 1 to 2 hours in patients with normal renal function [3].

When both substances are present at the same time, the kidney must handle an elevated solute load. That is the crux of the indirect interaction.

The Renal Clearance Overlap

The American College of Radiology (ACR) Manual on Contrast Media, updated in 2023, classifies contrast-induced nephropathy (CIN) as a genuine risk for patients with eGFR <60 mL/min/1.73 m², diabetes, or volume depletion [3]. CIN is defined as a serum creatinine rise of more than 0.5 mg/dL or more than 25% above baseline within 48 to 72 hours of contrast exposure [4].

NMN metabolite excretion has been quantified. A phase 1 dose-escalation trial published in 2023 in npj Aging (N=30) found that urinary MeNAM increased in a dose-dependent fashion after single oral NMN doses from 100 mg to 900 mg, confirming active renal handling of NAD precursor metabolites [2]. Adding that excretory burden on a kidney already transiently compressed by contrast osmolality is the mechanism worth managing, even if no trial has measured the combined effect directly.

Iodinated Contrast Agents: Risk Stratification for NMN/NR Users

Iodinated contrast agents, including iohexol (Omnipaque), ioversol (Optiray), and iodixanol (Visipaque), are used in CT scans, angiography, and interventional procedures. They are osmotically active and transiently reduce renal perfusion.

Who Is at Elevated Risk

Patients taking NMN/NR who face the greatest concern before an iodinated contrast procedure fall into three groups.

First, those with pre-existing CKD (eGFR <60). A 2019 meta-analysis in the American Journal of Kidney Diseases (N=13 studies, 5,216 patients) reported CIN incidence of 9.5% in CKD patients versus 1.8% in those with normal renal function [4]. Adding any renally-cleared supplement in this setting warrants a brief hold.

Second, patients on high-dose NMN/NR. Published human trials have tested doses up to 1,250 mg/day. The 2022 Nature Aging trial by Yoshino et al. (N=25 postmenopausal women) used 300 mg/day NMN for 10 weeks without renal adverse events in healthy subjects [5]. Higher doses generate proportionally more MeNAM for renal clearance, which matters if contrast is co-administered.

Third, patients who are dehydrated, elderly, or on NSAIDs or diuretics simultaneously, all of which compound contrast nephropathy risk per ACR guidance [3].

The Metformin Precedent

The ACR recommends withholding metformin before elective contrast-enhanced procedures in patients with eGFR <60, not because contrast reacts with metformin chemically, but because contrast-induced renal impairment can reduce metformin clearance and precipitate lactic acidosis [3]. The logic applies analogously to NMN/NR: if contrast transiently reduces GFR, metabolite accumulation from NAD precursors could increase, though the clinical consequence is far less severe than metformin-associated lactic acidosis. The parallel supports a conservative hold strategy.

Gadolinium-Based Contrast Agents: A Separate Risk Profile

Gadolinium-based contrast agents (GBCAs), used in MRI, carry a distinct risk: nephrogenic systemic fibrosis (NSF). The FDA added a class warning to all GBCAs in 2018 restricting their use in patients with eGFR <30 mL/min/1.73 m² who are not on dialysis [6].

NMN/NR and Gadolinium: No Direct Interaction, One Indirect Concern

No study has examined NMN or NR metabolism in the context of gadolinium co-administration. The indirect concern mirrors that with iodinated agents: renally-cleared NAD metabolites share excretory pathways with free gadolinium ions. In patients with eGFR <30, even modest additional renal solute pressure could theoretically delay gadolinium clearance, prolonging tissue exposure to free Gd³+ ions [6].

This remains a theoretical extrapolation. The practical instruction from the HealthRX medical team for any patient with eGFR <30 is to pause NMN/NR 24 hours before gadolinium MRI and discuss the procedure risk-benefit with the ordering radiologist, independent of supplementation status.

Macrocyclic vs. Linear GBCAs

Not all GBCAs carry equal NSF risk. Macrocyclic agents, including gadobutrol (Gadavist) and gadoteridol (ProHance), have tighter chelate structure and lower gadolinium release. Linear agents, including gadopentetate dimeglumine (Magnevist), carry higher NSF association per the FDA 2018 labeling update [6]. Patients on NMN/NR scheduled for MRI should confirm with their radiologist which agent is planned if they have any degree of renal impairment.

Practical Protocol: When and How to Hold NMN/NR Before Imaging

The following protocol is based on ACR contrast guidance [3], FDA GBCA labeling [6], and the renal pharmacokinetics of NMN metabolites documented in clinical trials [2].

For Patients with Normal Renal Function (eGFR ≥60)

Routine imaging with iodinated or gadolinium contrast carries low CIN or NSF risk at normal GFR. No mandatory NMN/NR hold is required by any published guideline. As a practical precaution, skipping the morning NMN/NR dose on the day of the procedure is reasonable and carries no measurable downside. NAD+ tissue stores are not meaningfully depleted by a single missed dose given the 2 to 4 week timescale of tissue NAD+ repletion seen in trials [5].

For Patients with Mild-to-Moderate CKD (eGFR 30 to 59)

Pause NMN/NR 24 hours before the contrast procedure. This clears one dosing cycle of MeNAM from renal circulation based on the urinary excretion kinetics reported by Okabe et al. [2]. Resume NMN/NR 48 hours after the procedure once creatinine has been checked and is stable relative to baseline. If creatinine rises more than 0.5 mg/dL, hold NMN/NR and contact the prescribing clinician.

For Patients with Severe CKD or Dialysis-Dependent Renal Failure (eGFR <30)

Hold NMN/NR 48 hours before any contrast-enhanced imaging. This population already requires specialist nephrology input before any contrast exposure. NMN/NR should remain on hold until the nephrologist confirms renal function has returned to pre-procedure baseline, typically 72 to 96 hours post-contrast [3].

NMN/NR and Other Common Imaging Concerns

Non-Contrast MRI and CT: No Issue

Non-contrast CT and MRI do not involve renally-cleared contrast agents. Patients on NMN/NR can proceed with non-contrast imaging without any supplementation hold. Nuclear medicine imaging, including PET scans using FDG (¹⁸F-fluorodeoxyglucose), also does not involve NAD-pathway interactions, though standard fasting protocols for FDG-PET apply independently.

X-Ray and Ultrasound

Plain radiographs and standard ultrasound involve no contrast agents in most settings. NMN/NR supplementation is not relevant to these modalities.

Can You Drink Alcohol While Taking NMN/NR?

This is a common secondary question. No published trial has tested NMN or NR in subjects with concurrent heavy alcohol use. Alcohol metabolism generates excess NADH via alcohol dehydrogenase, which shifts the NAD+/NADH ratio sharply toward NADH in hepatocytes [7]. That shift directly competes with the goal of NAD+ precursor supplementation, which is to raise free NAD+ availability. A 2021 review in Alcohol Research: Current Reviews noted that chronic alcohol use depletes hepatic NAD+ reserves measurably, creating a background state in which NMN/NR supplementation would be working against an ongoing biochemical drain [7].

Occasional moderate alcohol consumption, defined as up to one drink per day for women and two for men per the 2020 Dietary Guidelines for Americans, does not create a safety interaction with NMN/NR. Heavy or chronic drinking may blunt any NAD+-repletion benefit. There is no documented pharmacokinetic toxicity from combining alcohol and NMN/NR, only potential efficacy reduction.

What Clinical Trials Reveal About NMN/NR Pharmacokinetics

Understanding the pharmacokinetic profile of NMN and NR is necessary for interpreting any interaction risk with contrast agents.

Key Human Pharmacokinetic Data

The first-in-human NMN pharmacokinetic study by Irie et al. (2020, N=10 healthy men) published in Endocrine Journal found that a single 100 mg, 250 mg, or 500 mg oral NMN dose raised blood NAD+ metabolites within 2 to 3 hours of ingestion, with urinary excretion of MeNAM peaking at 4 to 8 hours post-dose [8]. This time course means that a 24-hour pre-procedure hold would clear one full dosing cycle and the peak renal excretion window for metabolites.

A separate dose-escalation study by Okabe et al. (2022, N=30) published in npj Aging tested 250 mg, 500 mg, and 1,000 mg/day NMN for 12 weeks. No clinically significant changes in serum creatinine, BUN, or urinalysis were seen across dose groups in subjects with normal baseline renal function [2]. This confirms that NMN alone does not harm healthy kidneys. The concern is exclusively about additive load in already-impaired renal function during contrast procedures.

NR-Specific Data

NR pharmacokinetics differ slightly from NMN. NR is cleaved to nicotinamide in the gut before absorption in some metabolic pathways. A 2016 study in Nature Communications by Trammell et al. (N=12) confirmed that oral NR raises blood NAD+ and its metabolites, including MeNAM, in a dose-dependent fashion [9]. The renal excretion profile is similar to NMN. The same 24-hour hold strategy applies to NR as to NMN before contrast-enhanced procedures.

NMN/NR Interactions Beyond Contrast: Brief Overview

Patients scheduled for imaging often ask about other interactions. Three are worth noting briefly.

Blood Pressure Medications

A 2023 pilot trial (N=22) found that 1,000 mg/day NMN for 8 weeks modestly reduced systolic blood pressure by approximately 3 mmHg in middle-aged adults [10]. This is a small magnitude. Patients on antihypertensives should be aware, but this does not affect imaging preparation.

Chemotherapy and Immunotherapy

Some oncologists caution against NAD+ precursor supplementation during active cancer treatment. NAD+ is a substrate for PARP enzymes involved in DNA repair, and theoretical concern exists that boosting NAD+ could support cancer cell DNA repair during genotoxic chemotherapy [11]. This is a separate clinical decision from contrast interaction and warrants oncologist input.

Anticoagulants

No pharmacokinetic interaction between NMN/NR and warfarin or direct oral anticoagulants (DOACs) has been published. Patients on anticoagulants scheduled for interventional procedures with contrast should follow their hematologist's anticoagulant hold protocol, independent of NMN/NR status.

Radiologist and Prescriber Communication Checklist

Patients taking NMN/NR should tell both their prescribing clinician and the radiology team. The following three points cover the relevant disclosures.

State the dose and brand: for example, "I take 500 mg NMN daily" or "I take 300 mg NR twice daily." This allows the radiologist to log it in the pre-procedure checklist.

Report your most recent eGFR if known. Contrast-risk stratification is eGFR-driven. An eGFR measured within the past 3 months is sufficient for most elective procedures per ACR guidance [3].

Confirm whether contrast is planned and which type. Some CT protocols are non-contrast. Knowing in advance allows appropriate supplementation management without unnecessary holds.